Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Esophagus Adenocarcinoma Clear all
Terminated Phase 1 Interventional

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

NCT03809624
View directory record Official record
Conditions
Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Interventions
INBRX-105 - PDL1x41BB antibody, Pembrolizumab
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
23
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Jul 23, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin

NCT00397904
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cetuximab, cisplatin, irinotecan hydrochloride, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Biological · Drug · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Jul 23, 2026, 8:14 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

NCT02016534
View directory record Official record
Conditions
Stomach Neoplasms
Interventions
AMG 337
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
New Haven, Connecticut • New York, New York • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 8:14 AM EDT
Completed Phase 1 Interventional

Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus

NCT01236443
View directory record Official record
Conditions
Barrett's Esophagus, CIS, High Grade Dysplasia
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Jul 23, 2026, 8:14 AM EDT
Terminated Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction

NCT00061958
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Stage III Esophageal Cancer, Stage IV Esophageal Cancer
Interventions
arsenic trioxide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Jul 23, 2026, 8:14 AM EDT
Completed No phase listed Observational

Cryotherapy -BEATS-RF Ablation Trial

NCT01882478
View directory record Official record
Conditions
Barrett's Esophagus With Persistent Dysplasia or, Early Esophageal Adenocarcinoma Post Radio Frequency Ablation
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Jul 23, 2026, 8:14 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers

NCT00177255
View directory record Official record
Conditions
Cancer
Interventions
Docetaxel, Capecitabine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jul 23, 2026, 8:14 AM EDT
Recruiting Not applicable Interventional

Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

NCT05530343
View directory record Official record
Conditions
Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophageal Adenocarcinoma
Interventions
Seattle protocol, WATS3D brushings
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
2,298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Gilbert, Arizona • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 8:14 AM EDT
Suspended Phase 2 Interventional

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

NCT06044311
View directory record Official record
Conditions
Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction
Interventions
Vactosertib, Standard of Care Preoperative Therapy
Drug
Lead sponsor
Melissa Lumish
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 8:14 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Obeticholic Acid for Prevention in Barrett's Esophagus

NCT04939051
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Biospecimen Collection, Esophageal Biopsy, Esophagogastroduodenoscopy, Liver Ultrasonographic Elastography, Obeticholic Acid, Placebo Administration, Questionnaire Administration
Procedure · Biological · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Kansas City, Kansas • Ann Arbor, Michigan • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 23, 2026, 8:14 AM EDT
Terminated Phase 2 Interventional Results available

Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy

NCT02392377
View directory record Official record
Conditions
Stage IB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIC Esophageal Adenocarcinoma
Interventions
Paclitaxel, Carboplatin, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Radiation Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Jul 23, 2026, 8:14 AM EDT
Completed No phase listed Observational

Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus

NCT00586872
View directory record Official record
Conditions
Barrett's Esophagus, Early Esophageal Adenocarcinoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Jul 23, 2026, 8:14 AM EDT
Completed Phase 2 Interventional

Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel

NCT00006245
View directory record Official record
Conditions
Esophageal Cancer
Interventions
alvocidib, paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Jul 23, 2026, 8:14 AM EDT
Recruiting Phase 1 Interventional

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

NCT05954312
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
VVD-130037, Docetaxel, Paclitaxel, Pembrolizumab
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
8
States / cities
Jacksonville, Florida • Sarasota, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 8:14 AM EDT
Active, not recruiting No phase listed Observational

National Cancer Institute "Cancer Moonshot Biobank"

NCT04314401
View directory record Official record
Conditions
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Carcinoma, Fallopian Tube Carcinoma, Gastric Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Metastatic Prostate Carcinoma, Multiple Myeloma, Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Chart Review, Paracentesis, Positron Emission Tomography
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
147
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 115 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 23, 2026, 8:14 AM EDT
Completed No phase listed Observational

A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

NCT04161781
View directory record Official record
Conditions
Esophagogastric Cancer, Esophagus Cancer, Esophageal Cancer, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma
Interventions
18F-BMS-986229 Injection, IV 18F-BMS-986229, PET/CT Scan
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 23, 2026, 8:14 AM EDT
Completed No phase listed Observational

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

NCT05461430
View directory record Official record
Conditions
Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Travera Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Utility Of Mutational Load As A Predictor For Endoscopic Treatment Response In Barrett's Esophagus

NCT04316975
View directory record Official record
Conditions
Barretts Esophagus With Dysplasia, Intramucosal Adenocarcinoma
Interventions
Study Driven Procurement of Biopsies
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Jul 23, 2026, 8:14 AM EDT
Suspended Phase 2 Interventional

Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus

NCT00048529
View directory record Official record
Conditions
Gastric Cancer, Esophageal Neoplasms
Interventions
T900607-sodium intravenous
Drug
Lead sponsor
Tularik
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
5
States / cities
Los Gatos, California • San Diego, California • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 8:14 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

NCT04248452
View directory record Official record
Conditions
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Interventions
Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
453
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 276 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 8:14 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Nitrates and IL-8 in Barrett's Esophagus

NCT04642690
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Jul 23, 2026, 8:14 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus

NCT00903136
View directory record Official record
Conditions
Esophageal Cancer, Precancerous Condition
Interventions
questionnaire administration, comparison of screening methods, diagnostic endoscopic procedure, esophagogastroduodenoscopy, tethered capsule endoscopy
Other · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Jul 23, 2026, 8:14 AM EDT
Completed Phase 2 Interventional

Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer

NCT00258323
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cisplatin, fluorouracil, Iressa, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Jul 23, 2026, 8:14 AM EDT
Completed Phase 2 Interventional

DX-8951f in Treating Patients With Metastatic Stomach Cancer

NCT00017212
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
exatecan mesylate
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
5
States / cities
Long Beach, California • Denver, Colorado • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Jul 23, 2026, 8:14 AM EDT